Lactobacillus GG in inducing and maintaining remission of Crohn's disease

Schultz, Michael; Timmer, Antje; Herfarth, Hans H; Sartor, R. Balfour; Vanderhoof, Jon A.; Rath, Heiko C.

doi:10.1186/1471-230x-4-5

Cited by 287 publications

(169 citation statements)

References 23 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…Although LGG has been shown to induce remission and prevent recurrence of IBD in patients 14 and in animal models of colitis, 12 a clinical trial designed to test the efficacy of LGG as an adjunct to standard therapy in children with Crohn's disease showed no beneficial effect of LGG in maintaining remission. 32 These results emphasize a current problem regarding the use of probiotic therapy, namely the difficulty determining the bioavailability of bacteria in the gastrointestinal tract.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble Proteins Produced by Probiotic Bacteria Regulate Intestinal Epithelial Cell Survival and Growth

et al. 2007

View full text Add to dashboard Cite

Background & Aims-Increased inflammatory cytokine levels and intestinal epithelial cell apoptosis leading to disruption of epithelial integrity are major pathologic factors in inflammatory bowel diseases. The probiotic bacterium Lactobacillus rhamnosus GG (LGG) and factors recovered from LGG broth culture supernatant (LGG-s) prevent cytokine-induced apoptosis in human and mouse intestinal epithelial cells by regulating signaling pathways. Here, we purify and characterize 2 secreted LGG proteins that regulate intestinal epithelial cell antiapoptotic and proliferation responses.

show abstract

Section: Discussionmentioning

confidence: 99%

“…10 Recent studies indicate that some Lactobacillus species function as probiotics and induce sustained remission in ulcerative colitis and pouchitis. [11][12][13][14] Lactobacillus rhamnosus GG (LGG), a bacterium used in the production of yogurt, is one of the best-studied Lactobacillus strains in clinical trials for IBD.…”

mentioning

confidence: 99%

Soluble Proteins Produced by Probiotic Bacteria Regulate Intestinal Epithelial Cell Survival and Growth

et al. 2007

View full text Add to dashboard Cite

show abstract

“…After 6 and 12 months treatment, the number of subjects remaining in remission was not different in the group receiving L. rhamnosus GG compared with a control group that received mesalazine (2400 mg/ d) or the group that received the combination treatment (48) . In contrast, the same probiotic did not show clinical benefit over control in the treatment of patients with CD (49)(50)(51) and was ineffective as primary therapy in patients with ileal pouch inflammation (52) . Similarly, Lactobacillus johnsonii was ineffective in preventing relapse in patients with inactive CD (53,54) .…”

Section: Proceedings Of the Nutrition Societymentioning

confidence: 86%

Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?

2014

View full text Add to dashboard Cite

Crohn's disease (CD) and ulcerative colitis (UC) are the two major phenotypes of inflammatory bowel diseases (IBD) which constitute a spectrum of chronic, debilitating diseases characterised by a relapsing inflammation of the intestinal mucosal lining. Evidence from a variety of disciplines implicates the intestinal microbiota in the pathogenesis of idiopathic IBD and their complications, including pouchitis. Many studies have reported a dysbiosis in IBD, characterised by a decrease in diversity, a decreased abundance of some dominant commensal members (such as Clostridium IV and XIVa) and an increase in detrimental bacteria (such as sulphate reducing bacteria and Escherichia coli). Therapies such as prebiotics and probiotics aim to selectively manipulate the intestinal microbiota and have been evaluated as an attractive therapeutic option with few side effects. The multispecies product VSL#3 was found effective in preventing and maintaining remission in pouchitis, whereas both VSL#3 and E. coli Nissle were effective in maintaining remission in UC. A more drastic approach to restore the composition of the microbiota and correct the underlying imbalance is a faecal microbiota transplantation (FMT). FMT has been successfully applied to treat patients with even recalcitrant Clostridium difficile infection. Particularly in UC, the majority of studies suggest that FMT may be an effective treatment option although the evidence is still limited. It is anticipated that our increasing knowledge on the composition and function of the intestinal microbiota components will allow in the future for a better selection of highly performing bacteria with specific functions required for specific benefits.

show abstract

“…A recent double-blinded placebo controlled trial randomized 11 patients with active CD to receive either LGG or placebo. There was no difference in at the rate of inducing remission for 6 months between the two groups [82].…”

Section: Probiotics To Treat Active CDmentioning

confidence: 88%

“…A recent double-blinded placebo controlled trial randomized 11 patients with active CD to receive either LGG or placebo. There was no difference at the rate of sustaining remission for 6 months between the two groups [82]. Another randomized, double blind study compared LGG vs. placebo in addition to standard maintenance therapy in a group of 75 children.…”

Section: Probiotics To Maintain Remission In CDmentioning

confidence: 99%